Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis,...
Company Valuation
Considering past and projected metrics, the stock is 'expensive' compared to its peers.
Target Price
The average target price of VKTX is 94 and suggests 181% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell